Post on 11-Jan-2016
transcript
1
OraQuickOraQuick®® ADVANCE ADVANCE™™ HIV 1/2 Antibody Test HIV 1/2 Antibody Test(Oral Fluid Specimen Type)(Oral Fluid Specimen Type)
Blood Products Advisory Committee Meeting
March 10, 2006
2
OraQuickOraQuick®® ADVANCEADVANCE™ ™ HIV 1/2 Test HIV 1/2 Test Oral Fluid ApplicationOral Fluid Application
Swab upper and lower gums once each with flat pad of test device
Insert device in developer vial. Read resultbetween 20 and 40 minutes
SIMPLE 2 STEP PROCEDURE:
3
Negative
Reactive Control
Line
SIMPLE RESULT INTERPRETATION:
One line = NEGATIVE
Two lines= PRELIMINARYPOSITIVE
Preliminary Positive
Reactive HIV-1/2
Test Line
OraQuickOraQuick®® ADVANCEADVANCE™ ™ HIV 1/2 Test HIV 1/2 Test Oral Fluid ApplicationOral Fluid Application
4
Sensitivity: Sensitivity: 99.3%99.3% (95% CIs: 98.4%-99.9%) (95% CIs: 98.4%-99.9%)
Specificity:Specificity: 99.8%99.8% (95% CIs: 99.6%- 99.9%)(95% CIs: 99.6%- 99.9%)
OraQuickOraQuick®® ADVANCEADVANCE™™ FDA FDA Approved Performance Claims Approved Performance Claims with Oral Fluidwith Oral Fluid
5
Surveillance of Post-Launch Surveillance of Post-Launch Performance of OraQuickPerformance of OraQuick®® ADVANCEADVANCE™™ with Oral Fluid with Oral Fluid
Two Data Sources:• Aggregate national performance in 2005 assessed using data provided by
state, city health agencies, HIV/AIDS service organizations:
Data from states representing 127,323 oral fluid tests
Overall specificity: 99.8% (99.77-99.82%)
• OraSure customer site survey of product performance in 2005:
Data obtained from 90 customer testing sites – 43,321 oral fluid tests
Overall specificity = 99.8% (99.75%-99.84%)
Overall, actual field performance corresponded to product claim
6
Investigation of Reports of False Investigation of Reports of False Positive Results at Particular SitesPositive Results at Particular Sites
Statistical Process Control (SPC) charting of 2005 data at 130 customer sites including those reporting high rates of false positives
– Almost all 130 sites studied (96%) had specificity within expected range (95% confidence interval)
– Elevated false positive rates were confined to a small number of sites– Analysis indicated a special cause operating at those sites
Product lots that were used at affected sites were also used by other sites in the same region and in other parts of the country with satisfactory performance
Data suggested that site- specific factor(s) were affecting product performance at a small number of sites
7
Suitability of Oral Fluid as a Suitability of Oral Fluid as a Specimen for HIV Self-Testing Specimen for HIV Self-Testing
• Simple, non-invasive sample collection• Established clinical performance- comparable to
blood/plasma testing (JAMA 2002; 288: 2960)
• Published studies have indicated a preference of clients for being tested for HIV by oral fluid. (J Acquir. Immune Syndr. 2005 38: 348-355)
• Independent survey of potential users indicated greater willingness to self-test with oral fluid (100%) compared to blood (64%). (OraSure Market Research; 2004)